38925-80-3

Basic information

• Product Name: 2,6-DICHLORO-9-(2-DEOXY-3,5,DI-O-(4-METHYLBENZOYL-BETA-D-ERYTHROPENTOFURANOSYL)-9H-PURINE)
• Synonyms: 2,6-DICHLORO-9-(2-DEOXY-3,5,DI-O-(4-METHYLBENZOYL-SS-D-ERYTHROPENTOFURANOSYL)-9H-PURINE;2,6-Dichloro-9-(3,5-di-O-p-toluyl-2-deoxy-beta-D-erythro-pentofuranosyl)purinepentofuranosyl)purine;2,6-DICHLORO-9-(2-DEOXY-3,5,DI-O-(4-METHYLBENZOYL-BETA-D-ERYTHROPENTOFURANOSYL)-9H-PURINE)
• CAS NO: 38925-80-3
• Molecular Formula: C₂₆H₂₂Cl₂N₄O₅
• Molecular Weight: 541.389
• Mol File: 38925-80-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,6-DICHLORO-9-(2-DEOXY-3,5,DI-O-(4-METHYLBENZOYL-BETA-D-ERYTHROPENTOFURANOSYL)-9H-PURINE)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLORO-9-(2-DEOXY-3,5,DI-O-(4-METHYLBENZOYL-BETA-D-ERYTHROPENTOFURANOSYL)-9H-PURINE)(38925-80-3)
• EPA Substance Registry System: 2,6-DICHLORO-9-(2-DEOXY-3,5,DI-O-(4-METHYLBENZOYL-BETA-D-ERYTHROPENTOFURANOSYL)-9H-PURINE)(38925-80-3)

Safety Data

• Hazardous Substances Data: 38925-80-3(Hazardous Substances Data)

Usage

General Description

2,6-DICHLORO-9-(2-DEOXY-3,5,DI-O-(4-METHYLBENZOYL-BETA-D-ERYTHROPENTOFURANOSYL)-9H-PURINE is a complex chemical compound with a molecular structure consisting of two chlorine atoms, a deoxyribose sugar molecule, and a purine base. It is a synthetic derivative of the nucleoside deoxyadenosine. The compound has potential applications in pharmaceuticals and biochemistry, as it may have biological activity against certain diseases or conditions. The specific properties and potential uses of this chemical compound are still under investigation and research.

Upstream product

• 7732-18-5 water 
• 5451-40-1 2,6 dichloropurine 
• 4330-21-6 2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl chloride 
• 5451-40-1 2,6-dichloro-7H-purine 

Downstream Products

• 133832-62-9 2-chloro-6-(hydroxylamino)-9-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-pentofuranosyl)purine 
• 4291-63-8 2-chloro-2'-deoxyadenosine 
• 680190-20-9 2-chloro-6-(6-tritylaminohexyl)aminopurine-2'-deoxy-3',5'-ditoluoyl-β-D-riboside 
• 4546-70-7 2-amino-2'-deoxyadenosine 
• 1017606-36-8 N9-2,6-di-(2'-pyridyl)-3',5'-di-(O-p-toluoyl)-β-D-1',2'-deoxyribofuranos-1-ylpurine 
• 136834-44-1 N-{9-{(2R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-tetrahydro-furan-2-yl}-6-[2-(4-nitro-phenyl)-ethoxy]-9H-purin-2-yl}-N-(3-imidazol-1-yl-propyl)-isobutyramide 
• 136834-42-9 Isobutyric acid (2R,3S,5R)-5-{2-[(3-imidazol-1-yl-propyl)-isobutyryl-amino]-6-[2-(4-nitro-phenyl)-ethoxy]-purin-9-yl}-2-isobutyryloxymethyl-tetrahydro-furan-3-yl ester 
• 136834-43-0 N-{9-((2R,4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-6-[2-(4-nitro-phenyl)-ethoxy]-9H-purin-2-yl}-N-(3-imidazol-1-yl-propyl)-isobutyramide 
• 146196-11-4 2-chloro-6-(cyclohexylamino)-9-(2'-deoxy-β-D-erythro-pentofuranosyl)-9H-purine 
• 917235-44-0 2,6-bis(benzoyloxymethyl)-9-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-furanosyl)purine 
• 259210-46-3 C₂₉H₂₈ClN₅O₅ 
• 259210-48-5 C₃₁H₃₂ClN₅O₅ 
• 259210-49-6 C₃₂H₃₄ClN₅O₅ 
• 259210-51-0 C₃₄H₃₈ClN₅O₅ 

Relevant articles and documents

The N-7 regioisomer of 2-chloro-2'-deoxyadenosine: synthesis, crystal structure, conformation, and stability

The nucleoside 6-amino-2-chloro-7-(2-deoxy-β-D-erythro-pentofuranosyl)-7H-purine 7 is readily accessible in two steps from 2,6-dichloropurine.The crystal structure of this unusual nucleoside reveals a bifurcated intramolecular hydrogen bond from the amino group to the O-5' with a weaker branch to the O-4' which imposes a syn glycosidic torsion angle: χ=67.0 deg.Semi-empirical calculations using AM1 parameters and optimisation of atomic co-ordinates derived from the crystal structure of 7 suggest that the molecule can adopt either anti or syn conformations with a slight preference for anti by 0.4 kcal mol-1 in heat of formation (ΔHf).NOE experiments in (CD3)2SO solution support the theoretical results indicating the presence of both syn and anti conformations and that the anti population is marginally favoured.The antileukaemic agent 2-chloro-2'-deoxyadenosine (6), the N-9 regioisomer of 7, was shown to be 9.6 kcal mol-1 more stable than 7.The increased stability of 6 over 7 seems attributable mainly to the relative stability of the aglycon tautomers 8 and 9, the energy difference between thase being 6.7 kcal mol-1 in favour of the 9H tautomer 8.Likewise, removal of the 2-chloro substituent has little effect on the tautomerism. Keywords: N-7 nucleoside; X-ray structure; semi-empirical; Conformation; NOE

A concise synthesis of isoguanine 2'-deoxyriboside and its adenine-like triplex formation when incorporated into DNA

A concise synthesis of 2'-deoxyisoguanosine is achieved whereby 2,6-dichloropurine is glycosylated using the Hoffer sugar to give a pair of beta-configured nucleoside N9/N7 regioisomers that are aminated using methanolic ammonia with concomitant deprotection of the sugar. Following chromatographic separation, pure 2-chloro-2'-deoxyadenosine was isolated as a single isomer. Displacement of the C2 chlorine atom using sodium benzyloxide, followed by hydrogenolysis of the benzyl group, gives 2'-deoxyisoguanosine. Isoguanine was incorporated into DNA by solid supported synthesis using the suitably protected 2-allyloxy-2'-deoxyadenosine phosphoramidite with the allyl group being removed post-oligomerisation under Noyori conditions. DNA melting studies showed isoguanine to exhibit adenine-like triplex formation.

Oligonucleotides containing N-2 substituted purines

This invention presents novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents--agents that are capable of specific hybridization with a nucleotide sequence of an RNA. Oligonucleotides are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.